Skip Ribbon Commands
Skip to main content

Uncooled Microwave Thyroid Ablation:

Established in practice, backed by evidence

​The first publication of clinical results from Gulsah Yildirim and Hakki Muammer Karakas, at Istanbul Fatih Sultan Mehmet Training and Research Hospital in Turkey, was published in May 2022.

They highlighted the safety, feasibility, performance of this system. Following up the first 40 patients, without major complications. Antibody levels and thyroid function tests have remained within normal limits with no significant change during follow-ups. Symptoms and cosmetic scores were significantly improved at all follow-up.​

​A second publication from the same authors confirmed the previous results and investigated successfully the option to improve the ablation in highly vascularized nodules by treating the ​ arterial feeder ("Artery first" approach), to obtain a good hemostasis.​

​At the CIRSE 2022 congress, two accepted abstracts reported similar results for the uncooled MWA system (Salvadori - Italy, Dionisio - Portugal). The VRR results were in line with what previously reported, confirming the repeatability of the procedure and the safety and performance features.​​

​Dionisio reported the disappearance of compressive and cosmetic symptoms after 1 month in 80% of patients.​​

​Subsequently, a novel publication on December 2022, from a single center study conducted by Eduardo Crespo at Hospital Universitario Fundacion Jiménez Diaz, in Madrid, Spain, further consolidated the evidence on safety, performance and clinical outcomes, with a solid follow up of 24 months.​​

​More recently, in October 2023, Dr. Aliberti and Dr. Casaril from Pederzoli Hospital in Peschiera del Garda, an Italian center of excellence for thyroid disease, published their experience on BTN Uncooled Microwave Ablation. A novel, dedicated procedure – the fluid-motion technique – was developed and implemented to obtain faster and potentially more effective ablations in all kinds of nodules, with a further confirmation of the results obtained at different European site.

*Overall results are calculated post-hoc by the authors​

More publications are in the making in Europe, that will be made available to the thyroid community soon.

 

 

 

 

 

TATO and TATOpro are a trademark of Biomedical srl.

TATO and TATOpro are manufactured by Biomedical srl and exclusively distributed by Terumo Europe NV in EMEA region.

Please contact your local Terumo sales representative  for more information.

What the evidence says

Discover our clinical evidence and case studies concerning this topic.

Do you need more info about this product?

Our sales representatives are here for you.

Contact us
Send us a message
I have read and accept Terumo Privacy And Cookies Policy and the Terms Of Use*
I wish to receive information and marketing updates from Terumo.
* mandatory fields

Thank you for contacting us!

We typically respond within 2 business days and will come back to you as soon as possible.

Are you a healthcare professional?

This webpage can include promotional content regarding one or several products of Terumo Europe, or some procedures concerning the use or implantation of such products. This webpage is exclusively intended for healthcare professionals and is in no event directed to the general public


For Pharmaceutical Professionals interested in our B2B products portfolio, please visit Terumo Pharmaceutical Solutions.